

Letermovir Liquid Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 66866-00020 3.1 30.09.2023 Date of first issue: 27.02.2015

Section 1: Identification

Product name Letermovir Liquid Formulation

Manufacturer or supplier's details

Company : MSD

Address 33 Whakatiki Street - Private Bag 908

Upper Hutt - New Zealand

Telephone 0800 800 543

0800 764 766 (0800 POISON) Emergency telephone number: 0800 243 622 (0800

CHEMCALL)

EHSDATASTEWARD@msd.com E-mail address

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical Restrictions on use Not applicable

Section 2: Hazard identification

GHS Classification

Reproductive toxicity : Category 2

repeated exposure (Oral)

Specific target organ toxicity - : Category 2 (Liver, spleen, Blood)

GHS label elements

Hazard pictograms

Signal word Warning

Hazard statements H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

Precautionary statements Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapours.



Letermovir Liquid Formulation

Date of last issue: 04.04.2023 Version Revision Date: SDS Number: 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

> P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	
Letermovir	917389-32-3	>= 1 -< 10	

Section 4: First-aid measures

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse. Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delaved

In case of eye contact

Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

Section 5: Fire-fighting measures

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Section 6: Accidental release measures

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

Section 7: Handling and storage



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation. Advice on safe handling : Do not breathe mist or vapours.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Letermovir	917389-32-3	TWA	0.4 mg/m3 (OEB 2)	Internal

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Hand protection

Particulates type



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Section 9: Physical and chemical properties

Appearance : liquid

Colour : clear

Odour : odourless

Odour Threshold : No data available

pH : 7.5

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n- : Not applicable



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : Not applicable

Section 10: Stability and reactivity

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Can react with strong oxidizing age

Conditions to avoid : None known.
Incompatible materials : Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Letermovir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 66866-00020
 Date of first issue: 27.02.2015

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Letermovir:

Remarks : No data available

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Components:

Letermovir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection

Result: negative

Germ cell mutagenicity -

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Assessment

Not classified based on available information.

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Letermovir:



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, female Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility

Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: LOAEL: 180 mg/kg body weight

Result: No effects on fertility

Remarks: The significance of these findings for humans is not

certain.

Test Type: Fertility/early embryonic development

Species: Monkey, male Application Route: Oral

Fertility: NOAEL: 240 mg/kg body weight

Result: No effects on fertility

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Developmental Toxicity: LOAEL: 250 mg/kg body weight

Result: Embryo-foetal toxicity

Remarks: Maternal toxicity observed.

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: LOAEL: 225 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.,

Abortion

Remarks: Maternal toxicity observed.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Liver, spleen, Blood) through prolonged or repeated exposure if swallowed.

Components:

Letermovir:

Exposure routes : Ingestion

Target Organs : Liver, spleen, Blood

Assessment : May cause damage to organs through prolonged or repeated

exposure.



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 66866-00020
 Date of first issue: 27.02.2015

Repeated dose toxicity

Components:

Letermovir:

Species : Mouse

NOAEL : 40 mg/kg

LOAEL : 100 mg/kg

Application Route : Oral

Exposure time : 13 Weeks

Target Organs : Liver, spleen

Species : Rat

NOAEL : 150 mg/kg Application Route : Oral Exposure time : 26 Weeks

Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 100 mg/kg
LOAEL : 200 - 250 mg/kg

Application Route : Oral
Exposure time : 39 Weeks
Target Organs : Kidney

Species : Rat
NOAEL : 60 mg/kg
LOAEL : 180 mg/kg
Exposure time : 13 Weeks

Target Organs : Testis, Blood, Liver, spleen, Immune system

Species : Monkey
NOAEL : 30 mg/kg
LOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Target Organs : Blood

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Letermovir:

Ingestion : Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizzi-

ness, Fatigue, Back pain, Oedema, Rash, muscle pain



Letermovir Liquid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 30.09.2023
 66866-00020
 Date of first issue: 27.02.2015

Section 12: Ecological information

Ecotoxicity

Components:

Letermovir:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 16 mg/l

Exposure time: 96 h

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 1 mg/l

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 1.2 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms

EC50: > 972 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

Method: OECD Test Guideline 209

NOEC: 29.6 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

Persistence and degradability

Components:

Letermovir:

Biodegradability : Result: rapidly degradable

Biodegradation: 50 % Exposure time: 6.7 d

Bioaccumulative potential

Components:

Letermovir:

Partition coefficient: n-

octanol/water

log Pow: 2.29

Mobility in soil

Components:

Letermovir:

Distribution among environ-

mental compartments

log Koc: 3.46

Other adverse effects

No data available

Section 13: Disposal considerations

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable



Letermovir Liquid Formulation

Date of last issue: 04.04.2023 Version Revision Date: SDS Number: 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

Subsidiary risk Not applicable Packing group Not applicable Labels Not applicable Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen- : Not applicable

ger aircraft)

IMDG-Code

UN number Not applicable Not applicable Proper shipping name Class Not applicable Subsidiary risk Not applicable Packing group Not applicable Labels Not applicable **EmS Code** Not applicable Marine pollutant Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

NZS 5433

UN number Not applicable Not applicable Proper shipping name Class Not applicable Not applicable Subsidiary risk Not applicable Packing group Labels Not applicable Hazchem Code Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

HSR100425 Pharmaceutical Active Ingredients Group Standard

HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS not determined

DSL not determined



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

IECSC : not determined

Section 16: Other information

Revision Date : 30.09.2023

Further information

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate: NOM - Official Mexican Norm: NTP - National Toxicology Program: NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only



Letermovir Liquid Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 30.09.2023 66866-00020 Date of first issue: 27.02.2015

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN